Seraforte
Seraforte, licence 80130717: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- FLASER FORTE, SERRATEN
- Licence holder
- Aone Pharma Inc.
- NPN or DIN-HM
- 80130717
- Status
- Active licence
- Licence date
- 22 April 2024
- Revision date
- 7 June 2024
- Form
- Capsule, libération retardée
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Stéarate de magnésium, Farine de riz brun, Gomme de gellane, Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 18.0 Année(s) | 1.0 Capsule | 1.0 Tous les jours |
| Adultes | minimum: 18.0 Année(s) | 3.0 Capsule | 1.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Proteolytic Enzyme. Helps reduce and/or relieve postoperative cheek swelling and/or pain after dental surgery. Helps to reduce (symptoms such as) pain, quantity of secretion, inability to perceive smell and stuffy nose from ear, nose and/or throat infections. Mucolytic enzyme that helps break down mucous to reduce (symptoms such as) pain, quantity of secretion, inability to perceive smell and stuffy nose from ear, nose and/or throat infections. Mucolytic enzyme that helps break down mucous.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80130717
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2024. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.